Roche (Basel, Switzerland) has announced results from its Phase III IMpower130 trial. The findings demonstrate that Tecentriq® (atezolizumab) plus chemotherapy (carboplatin and Abraxane®) helped individuals with metastatic non-squamous non-small cell lung cancer (NSCLC), who lived significantly longer compared with those who received chemotherapy alonelive significantly longer compared with chemotherapy alone.
The company has announced that IMpower130 met its overall survival and progression-free survival co-primary endpoints.
IMpower130 is a Phase III, multicenter, open-label, randomized study evaluating the efficacy and safety of Tecentriq in combination with carboplatin and nab-paclitaxel versus chemotherapy (carboplatin and nab-paclitaxel) alone for chemotherapy-naïve patients with stage IV non-squamous NSCLC.
The study enrolled 724 people who were randomized (2:1) to receive Tecentriq plus carboplatin and nab-paclitaxel (Arm A), or Carboplatin and nab-paclitaxel (Arm B, control arm).
The co-primary endpoints were progression-free survival as determined by the investigator using RECIST v1.1 in all randomized patients without an EGFR or ALK mutation (intention-to-treat wild-type) or overall survival in the intention-to-treat wild-type population.
Safety for the Tecentriq and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination.
“The results of the IMpower130 study add to the growing evidence showing the clinical benefit of Tecentriq-based combinations in the treatment of advanced non-squamous NSCLC,” explained Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “We will share these results with global health authorities with the goal of bringing this potential treatment option to people with this disease.”
Currently, Roche has eight Phase III lung cancer studies underway evaluating Tecentriq alone or in combination with other medicines. This is the third positive Phase III study evaluating Tecentriq alone or in combination to demonstrate an overall survival benefit for NSCLC patients.